Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions

Italian Heart Journal

Volumn 5, Issue 8, 2004, Pages 618-623

  Scelsi, Laura ^a   Ghio, Stefano ^a   Campana, Carlo ^a   D'Armini, Andrea Maria ^a   Serio, Alessandra ^a   Klersy, Catherine ^a   Piovella, Franco ^a   Viganò, Mario ^a   Tavazzi, Luigi ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Epoprostenol; Prostaglandins; Pulmonary embolism; Pulmonary hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; PROSTACYCLIN;

ARTICLE; DOPPLER ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEASIBILITY STUDY; FEMALE; HEART CATHETERIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; PULMONARY HYPERTENSION; REGRESSION ANALYSIS; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; ECHOCARDIOGRAPHY, DOPPLER; EPOPROSTENOL; EXERCISE TOLERANCE; FEASIBILITY STUDIES; FEMALE; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; REGRESSION ANALYSIS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 16644387305     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
2. Moncada S, Gryglewski RJ, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-5.
3. Graf H. Endothelial control of cell migration and proliferation. Eur Heart J 1993; 14 (Suppl 1): 183-6.
4. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol 1995; 75: 3A-10A.
5. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacylin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96: 2782-4.
6. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-82.
7. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-8.
8. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465-72.
9. D'Armini AM, Cattadori B, Monterosso C, et al. Pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension: hemodynamic characteristics and changes. Eur J Cardiothorac Surg 2000; 18: 696-702.
10. Bell WR, Simon TL. Current status of pulmonary thromboembolic disease: pathophysiology, diagnosis, prevention, and treatment. Am Heart J 1982; 103: 239-62.
11. Callegari G, D'Armini AM, Viganò M, Fracchia C. Lung transplantation: the new point of view of an Italian center. Monaldi Arch Chest Dis 2000; 55: 283-6.
12. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80: 151-5.
13. McLaughlin VV, Gerthner DE, Pannella MM, Hesse DM, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999; 130: 740-3.
14. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-7.
15. Auger WR, Fedullo PF, Moser KM, Buchbinder M, Peterson KL. Chronic major-vessel thromboembolic pulmonary artery obstruction: appearance at angiography. Radiology 1992; 182: 393-8.
16. Ghio S, Raineri C, Scelsi L, et al. Usefulness and limits of transthoracic echocardiography in the evaluation of patients with primary and chronic thromboembolic pulmonary hypertension. J Am Soc Echocardiogr 2002; 15: 1374-80.
17. Gavazzi A, Berzuini C, Campana C, et al. Value of right ventricular ejection fraction in predicting short-term prognosis of patients with severe chronic heart failure. J Heart Lung Transplant 1997; 16: 774-85.
18. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-7.
19. Nagaya N, Sasaki N, Ando M, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003; 123: 338-43.
20. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-23.
21. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-9.